Long-term health outcomes in pediatric inflammatory bowel disease: A population-based study

2009 ◽  
Vol 15 (1) ◽  
pp. 56-62 ◽  
Author(s):  
Pieta Turunen ◽  
Merja Ashorn ◽  
Anssi Auvinen ◽  
Sari Iltanen ◽  
Heini Huhtala ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Health Outcomes ◽  
Bowel Disease ◽  
Population Based ◽  
Population Based Study ◽  
Pediatric Inflammatory Bowel Disease ◽  
Inflammatory Bowel

scholarly journals Tracking of Height and Body Mass Index (BMI) in Pediatric Inflammatory Bowel Disease: A 15-Year Population-Based Study

2011 ◽  
Vol 140 (5) ◽  
pp. S-392
Author(s):  
Seema Mehta ◽  
Hoda M. Malaty ◽  
Elizabeth A. Garnett ◽  
Bincy P. Abraham ◽  
Carolyn Thibodeaux ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Inflammatory Bowel Disease ◽  
Body Mass ◽  
Bowel Disease ◽  
Population Based ◽  
Population Based Study ◽  
Pediatric Inflammatory Bowel Disease ◽  
Inflammatory Bowel

Mo1243 Post-Operative Complications in Pediatric Inflammatory Bowel Disease: A Population-Based Study

2013 ◽  
Vol 144 (5) ◽  
pp. S-615
Author(s):  
Eugénie Penninck ◽  
Julia Salleron ◽  
Mathurin Fumery ◽  
Guillaume Savoye ◽  
Dominique Turck ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Population Based ◽  
Population Based Study ◽  
Pediatric Inflammatory Bowel Disease ◽  
Operative Complications ◽  
Inflammatory Bowel ◽  
Post Operative Complications

Novel Targets For Therapeutic Intervention in Inflammatory Bowel Disease. What is the Best Way to Assess the Safety Profile of a Drug?

2019 ◽  
Vol 25 (1) ◽  
pp. 57-63 ◽  
Author(s):  
Clara Yzet ◽  
Stacy S. Tse ◽  
Maia Kayal ◽  
Robert Hirten ◽  
Jean-Frédéric Colombel
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Evaluation Process ◽  
Population Based ◽  
Stage Of Development ◽  
Remission Rates ◽  
Safety Parameters ◽  
Post Marketing ◽  
Inflammatory Bowel

The emergence of biologic therapies has revolutionized the management of inflammatory bowel disease (IBD) by halting disease progression, increasing remission rates and improving long-term clinical outcomes. Despite these well-described benefits, many patients are reluctant to commence therapy due to drug safety concerns. Adverse events can be detected at each stage of drug development and during the post-marketing period. In this article, we review how to best assess the safety parameters of new IBD medications, from the earliest stage of development to population-based registries, with a focus on the special populations often excluded from the evaluation process.

Sign in / Sign up

Export Citation Format

Share Document